Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Eisai Files First Approval Application For Novel Breast Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

Eisai has filed an application for approval of one of its drugs for treating breast cancer in Switzerland. Eisai discovered and developed the compound used in its E7389 (halichondrin B) and plans to apply by the end of the year for approval in Japan, the rest of Europe and the United States. Eisai is also conducting clinical trials for using the drug in other types of cancer, including for treating prostate cancer in Europe and the United States. (Click here for more - a subscription may be required

Table

View full table

Tags:
Latest Headlines

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs

GSK Looks Forward To RSV Vaccine Competition

See All
UsernamePublicRestriction

Register

SC072320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By